Double-Blind, Randomized Trial of Docetaxel Plus Vandetanib Versus Docetaxel Plus Placebo in Platinum-Pretreated Metastatic Urothelial Cancer

PURPOSE: Vandetanib is an oral once-daily tyrosine kinase inhibitor with activity against vascular endothelial growth factor receptor 2 and epidermal growth factor receptor. Vandetanib in combination with docetaxel was assessed in patients with advanced urothelial cancer (UC) who progressed on prior...

Cur síos iomlán

Na minha lista:
Sonraí Bibleagrafaíochta
Main Authors: Choueiri, Toni K., Ross, Robert W., Jacobus, Susanna, Vaishampayan, Ulka, Yu, Evan Y., Quinn, David I., Hahn, Noah M., Hutson, Thomas E., Sonpavde, Guru, Morrissey, Stephanie C., Buckle, Geoffrey C., Kim, William Y., Petrylak, Daniel P., Ryan, Christopher W., Eisenberger, Mario A., Mortazavi, Amir, Bubley, Glenn J., Taplin, Mary-Ellen, Rosenberg, Jonathan E., Kantoff, Philip W.
Formáid: Artigo
Teanga:Inglês
Foilsithe: American Society of Clinical Oncology 2012
Ábhair:
ORIGINAL REPORTS
Rochtain Ar Líne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4104290/
https://ncbi.nlm.nih.gov/pubmed/22184381
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2011.37.7002
Clibeanna: Cuir Clib Leis
Gan Chlibeanna, Bí ar an gcéad duine leis an taifead seo a chlibeáil!

Míreanna Comhchosúla